The Unusual Presentation of Bilateral Proptosis Presents a Dilemma in the Case of Juvenile Myelomonocytic Leukemia

Himanshu Gohatre1 Deepali Ambike1 Garima Singh Deo1 Rajesh Kulkarni1 Tushar Patil2

1 Department of Pediatrics, PCMC’s Post Graduate Institute YCM Hospital, Pune, India
2 Department of Pathology, PCMC’s Post Graduate Institute YCM Hospital, Pune, India

Introduction

Leukemias are among the most common white cell malignancies in the children. White cell malignancies are broadly of three types: lymphoid neoplasms, myeloid neoplasms, and histiocytic neoplasms. Lymphoid leukemia is more common and has a better prognosis than most of the myeloid leukemias. The incidence of myeloid leukemia relatively increases in the adolescent age group and is associated with several chromosomal abnormalities. Lymphoid leukemias have a better prognosis and survival rates than myeloid leukemias. Increased supportive care and prolonged hospitalization are required in patients with leukemia.

Case Report

A 4-year-old girl was admitted with complaints of intermittent low-grade fever for 15 days. Following the onset of the fever spike, the patient started developing swelling around both eyes (proptosis), which was symmetrical, insidious in onset, and progressively increasing in size, which led to protrusion of both eyes (►Fig. 1). This was associated with conjunctival hemorrhage and dry eyes. Proptosis was not associated with pain or diminution of vision. Also, there was no history of significant weight loss or a history of malignancy in the family.

Peripheral blood smear (PBS: ►Fig. 2) was suggestive of marked leukocytosis with increased blast cells and monocytoid cells. PBS also revealed the presence of myeloblasts (8%), promyelocytes (3%) myelocytes (20%), and metamyelocytes (18%).
band cells (9%), and dysplastic monocytes (18%). Auer rods were not visible in the blasts. Additionally shown were mild thrombocytopenia and normocytic normochromic anemia.

Following a bone marrow aspirate biopsy, hypercellular marrow with a predominately myeloid series was discovered. Fifteen percent myeloblasts (n.v.: 5%), a large number of early myeloid cells, and relatively suppressed erythroid and megakaryocytic series were seen, which were suggestive of a myeloproliferative neoplasm.

Bone marrow biopsy was also done, which showed hypercellular marrow, with a myeloid series predominance and marked suppression of erythroid and megakaryocytic series. The myeloid series had progressive maturation with a prominent monocytic series. Blasts were 9% and a provisional diagnosis of JMML was made. Fluorescence in situ hybridization (FISH) for BCR-ABL1 was negative, strongly suggesting JMML.

Thyroid function test and chest X-ray done were within normal limits. Lumbar puncture and transpalpebral biopsy were not done because the patient was not vitally stable.

Since hematopoietic stem cell transplantation (HSCT) is not offered at our hospital, the patient was referred to a higher oncology and diagnostic center for the required procedure. Standard protocol treatment was initiated and the patient has a relatively better general condition now as per the telephonic conversation with the parents.

Discussion

JMML is an uncommon and life-threatening disorder affecting hematopoietic stem cells in infancy and early childhood. Formerly known as juvenile myelogenous leukemia, it accounts for 1% of all cases of childhood leukemia with an incidence of 1.2 cases/million with a median age of 2 years and male predominance (male-to-female ratio of 2.5).\(^1\)\(^{–}\)\(^5\)

In JMML, the differentiation pathway is directed toward monocytic differentiation, and the JMML cell’s progenitor colonies exhibit a range of differentiations, encompassing blasts, monocytes, promonocytes, and macrophages.\(^1\) Most JMML patients have mutations that activate the RAS oncoprotein pathway, like NRAS, NF1, and PTPN11; germline RAS mutations have been linked to a better prognosis than somatic RAS mutations. Somatic PTPN11 mutations are among the common RAS pathway mutations in JMML.\(^6\)\(^{–}\)\(^9\)

JMML is more common in patients with neurofibromatosis type 1 (NF-1) and Noonan’s syndrome.\(^10\) Most of the patients of Noonan’s syndrome with JMML have a better prognosis and a high probability of spontaneous resolution.\(^11\)

![Fig. 1 Periorbital infiltrates leading to proptosis.](image1)

![Fig. 2 The peripheral blood film (PBF) of the patient. (a) PBF showing leukocytosis with increased blast cells of all maturation stages. (b) Myeloblasts. (c, d) Metamyelocytes and monocyte suggesting monocytosis.](image2)
JMML patients may exhibit symptoms such as fever, rash, cough, pallor, infections, and lymphadenopathy. Abdominal examination usually has positive findings of splenomegaly and hepatomegaly. The presence of splenomegaly is a consistent feature in all cases and is essential for diagnosing JMML. Eczema, xanthoma, café-au-lait spots, and juvenile xanthogranuloma are a few of the skin lesions seen in these patients. If the casitas B-lineage lymphoma (CBL) gene or NF1 gene germline mutations are present, then these patients can also have café-au-lait spots. Eye/orbital involvement is uncommon in JMML, with only a few such cases registered in the published literature. Orbital involvement is more prevalent among children, particularly those from nonindustrialized countries. Typically unilateral, it can manifest at any leukemia stage and may precede systemic disease indicators. In a series of 32 leukemic Ugandan children, orbito-ocular manifestation at the presentation constituted 18.8% of cases. Risk factors include lower socioeconomic status, impaired delayed hypersensitivity skin tests, diminished CD4/CD8 lymphocyte counts, and monocytic leukemia. Cases with the initial orbital disease often develop systemic leukemic features in a year of diagnosis. Proptosis, mainly caused by a combination of orbital muscle infiltration, leukemic infiltrates, venous blockage, and retrobulbar hemorrhage, is the predominant orbital sign in these cases.

Respiratory distress with a cough secondary to intestinal infiltrates is usually seen when the respiratory system is involved. In others, tractable diarrhea, gastrointestinal infections with hemorrhagic manifestations are seen in patients with gastrointestinal involvement. Central nervous system involvement is rare in JMML.

There are multiple infections that mimic JMML, like cytomegalovirus (CMV), Epstein–Barr virus (EBV), parvovirus B19, human herpes virus 6 (HHV-6), and congenital intrauterine infections.

These nonmalignant infections should be ruled out in patients with high suspicion of JMML; chromosomal and/or genetic aberrations and mutation of the RAS pathway can be used to help rule out these infections.

Peripheral blood film (PBF) examination is essential in establishing the diagnosis. PBF usually shows a shift toward immaturity in the granulocytes with leukocytosis, monocytosis thrombocytopenia (which can be severe), and anemia. Absolute monocytosis of greater than 1,000/mm³ is a diagnostic criterion for the JMML. At the same time, it can be a feature of some underlying infection; thus, it is neither specific nor sensitive.

Bone marrow examination has myeloid predominance and hypercellularity. Myeloid progenitors and blasts are usually increased, but blast counts are usually less than 20% and Auer rods are not seen. They also have an abundance of monocyes (around 5–10%). In other lineages, erythroid progenitors are megaloblastic and megakaryocytes are decreased in number.

JMML is diagnosed using the 2016 revision of the WHO classification as a basis for diagnosis (Table 1).

Cytogenetics for monosomy 7, genomic sequencing for KRAS, PTPN11, CBL, and NF1 genes to find molecular alterations, and STAT-5 phosphorylation assay of CBL gene and

**Table 1** Diagnostic criteria for JMML per the 2016 revision to WHO classification

<table>
<thead>
<tr>
<th>JMML diagnostic criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>I. Clinical and hematological features (all 4 features mandatory)</strong></td>
</tr>
<tr>
<td>• PBF monocyte count ≥1 × 10⁹/L</td>
</tr>
<tr>
<td>• Blast percentage in PBF and BM &lt;20%</td>
</tr>
<tr>
<td>• Splenomegaly</td>
</tr>
<tr>
<td>• Absence of Philadelphia chromosome (BCR-ABL1 rearrangement)</td>
</tr>
<tr>
<td><strong>II. Genetic studies (1 finding sufficient)</strong></td>
</tr>
<tr>
<td>• Somatic mutation in PTPN11 or KRAS or NRAS⁴</td>
</tr>
<tr>
<td>• Clinical diagnosis of NF1 or NF1 mutation</td>
</tr>
<tr>
<td>• Germ line CBL mutation and loss of heterozygosity of CBL⁵</td>
</tr>
<tr>
<td><strong>III. In addition to the clinical and hematological features mentioned under I, the following requirements must be met for patients without genetic features</strong></td>
</tr>
<tr>
<td>• Monosomy 7 or any other chromosomal abnormality or at least 2 of the following criteria:</td>
</tr>
<tr>
<td>– Hemoglobin F increased for age</td>
</tr>
<tr>
<td>– Myeloid or erythroid precursors on PB smear</td>
</tr>
<tr>
<td>– GM-CSF hypersensitivity in colony assay</td>
</tr>
<tr>
<td>– Hyperphosphorylation of STAT5</td>
</tr>
</tbody>
</table>

Abbreviations: BM, bone marrow; CBL, casitas B-lineage lymphoma; GM-CSF, granulocyte-macrophage colony-stimulating factor; JMML, juvenile myelomonocytic leukemia; KRAS, Kirsten rat sarcoma; NF1, neurofibromin 1; NRAS, neuroblastoma rat sarcoma; PBF, peripheral blood film; PTPN11, protein tyrosine phosphatase nonreceptor type.

⁴Germ line mutations (indicating Noonan syndrome) needs to be excluded.

⁵Occasional cases with heterozygous splice site mutations.
high hemoglobin F levels are some of the other investigations done to support and classify diagnosed JMML.\textsuperscript{1,23}

The following initial factors are associated with a lower chance of survival: hepatomegaly, bleeding, thrombocytopenia, older age (>2 years), female gender, higher blast, and normoblast counts in peripheral blood.

The only definitive therapy is HSCT for most of the patients but has a greater rate of relapse of 30 to 40%.\textsuperscript{24}

Intensive chemotherapy by acute myeloid leukemia (AML) protocols could induce temporary remission in JMML but is very detrimental to the patient, and the European Working Group of Myelodysplastic Syndrome (EWOG-MDS) trial showed no major variation in mortality and survival rates in patients on these AML protocols as compared to less intensive treatment.\textsuperscript{24} As a chemotherapeutic agent, fludarabine in high doses (30 mg/m\textsuperscript{2}) has been used as a cytoreducive therapy in aggressive cases before HSCT.\textsuperscript{25} Prior to this for many decades 6-mercaptopurine (50 mg/m\textsuperscript{2}) or cytarabine (40 mg/m\textsuperscript{2}) was used prior to HSCT, but none of these therapies have shown any improvement in the outcome of patients with JMML.\textsuperscript{26}

In March 2011, azacitidine had been approved for JMML therapy by the Food and Drug Administration (FDA). Following FDA approval, a study in Slovakia used azacitidine in doses of 75 mg/m\textsuperscript{2} as a bridging therapy before the HSCT and observed favorable response with fewer adverse effects. Another similar study used azacitidine monotherapy in newly diagnosed cases of JMML following favorable outcomes shown in the Slovakia-based study.\textsuperscript{27} In other studies, Hashmi et al. reported the disappearance of monosomy 7 clones in JMML without HSCT and sustained remission after azacitidine treatment. Therefore, the majority of patients currently receive azacitidine as standard care prior to undergoing HSCT.\textsuperscript{28}

Patient Consent
Declaration of the patient consent form
Written, Informed Patient Consent: Obtained
All authors have read and approved the final manuscript.

Funding
None.

Conflict of Interest
None declared.

References
12 Urs L, Stevens L, Kahwash SB. Leukemia presenting as solid tumors: report of four pediatric cases and review of the literature. Pediatr Dev Pathol 2008;11(05):370–376